Causes of death in the full cohort and according to IGHV-MS
| Cause of death . | Full cohort, no. of deaths (% of all patients who died from this cause/% of total deaths attributable to this cause) . | IGHV-M, no. of deaths (% of all patients with IGHV-M who died from this cause/% of total deaths in patients with IGHV-M attributable to this cause) . | IGHV-UM, no. of deaths (% of all patients with IGHV-UM who died from this cause/% of total deaths in patients with IGHV-UM attributable to this cause) . |
|---|---|---|---|
| Total deaths | 169 of 300 (56%) | 35 of 88 (40%) | 92 of 126 (73%) |
| CLL | 69 (23/41) | 9 (10/26) | 44 (35/48) |
| Richter transformation | 24 (8/14) | 5 (6/14) | 12 (10/13) |
| Solid tumor | 18 (6/11) | 5 (6/14) | 8 (6/9) |
| Other hematologic neoplasm | 15 (5/9) | 5 (6/14) | 2 (2/2) |
| Infection in remission | 11 (4/7) | 3 (3/9) | 5 (4/5) |
| Nonrelapse mortality after allogeneic SCT | 14 (5/8) | 1 (1/3) | 13 (10/14) |
| Other | 2 (1/1) | 2 (2/6) | 0 (0/0) |
| Unknown | 16 (5/9) | 5 (6/14) | 8 (6/9) |
| Cause of death . | Full cohort, no. of deaths (% of all patients who died from this cause/% of total deaths attributable to this cause) . | IGHV-M, no. of deaths (% of all patients with IGHV-M who died from this cause/% of total deaths in patients with IGHV-M attributable to this cause) . | IGHV-UM, no. of deaths (% of all patients with IGHV-UM who died from this cause/% of total deaths in patients with IGHV-UM attributable to this cause) . |
|---|---|---|---|
| Total deaths | 169 of 300 (56%) | 35 of 88 (40%) | 92 of 126 (73%) |
| CLL | 69 (23/41) | 9 (10/26) | 44 (35/48) |
| Richter transformation | 24 (8/14) | 5 (6/14) | 12 (10/13) |
| Solid tumor | 18 (6/11) | 5 (6/14) | 8 (6/9) |
| Other hematologic neoplasm | 15 (5/9) | 5 (6/14) | 2 (2/2) |
| Infection in remission | 11 (4/7) | 3 (3/9) | 5 (4/5) |
| Nonrelapse mortality after allogeneic SCT | 14 (5/8) | 1 (1/3) | 13 (10/14) |
| Other | 2 (1/1) | 2 (2/6) | 0 (0/0) |
| Unknown | 16 (5/9) | 5 (6/14) | 8 (6/9) |
SCT, stem cell transplantation.